Findings suggest that underlying inflammation may be the cause of increased rates of CV events for patients with IBD.
New Cleveland Clinic research shows a troubling disparity in Black patients’ access to advanced inflammatory bowel disease therapies when compared with white patients. This lack of access to advanced treatments can have severe health consequences for patients, including more complications and hospitalizations.
A team of clinicians, statisticians and computer analysts came together to examine the impact of biological therapies in the treatment of adult and pediatric Crohn’s disease.
A study of patients treated for Crohn’s disease at Cleveland Clinic found that rates of abdominal surgery were significantly lower in patients who received biologics for six months or more, compared with those treated for less than six months. In this article, Jacob Kurowski, MD, discusses his findings.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Tumor necrosis factor-α inhibitors (TNFis) have transformed care for rheumatoid arthritis and other autoimmune diseases, but they also are associated with higher risks of serious and opportunistic infections than traditional disease-modifying antirheumatic drugs. In this article, Cassandra Calabrese, DO, discusses balancing the benefits of biologic therapies with the risks of infection.
Clinicians do not administer reactive TDM or objective disease activity assessments prior to making changes in biologic therapies in almost a third of patients with IBD.
After two decades of using biologics for IMIDs, we now have an armamentarium, including five drugs and a number of biosimilars, that continues to grow at a record pace.
Whether you plan to complete the entire series or prefer to pick a handful of individual webcasts most relevant to your practice, don’t miss this complimentary educational opportunity.
Denosumab and romosozumab work on different pathways but offer new options for patients with low bone mass as primary therapy and for those unresponsive to or contraindicated for bisphosphonates.
Individuals with clinically unapparent HBV and concomitant immune-mediated inflammatory diseases (IMIDs) (e.g., rheumatoid arthritis, psoriasis, inflammatory bowel disease and others) are particularly vulnerable to HBV reactivation when immunosuppressed.